ACIU Quote, Financials, Valuation and Earnings

Kuros Biosciences Ltd. has a net margin of -1688.87% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -75.88% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.

AC Immune SA has a consensus price target of $9.20, signalling upside risk potential of 223.77%. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that AC Immune SA has higher upside potential than Kuros Biosciences Ltd., analysts believe AC Immune SA is more attractive than Kuros Biosciences Ltd..

AC Immune SA has a beta of 1.637, which suggesting that the stock is 63.73% more volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.447%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $1.2M, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. AC Immune SA's net income of -$19.8M is higher than Kuros Biosciences Ltd.'s net income of --. Notably, AC Immune SA's price-to-earnings ratio is -- while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 55.40x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

EvoNext Holdings SA has a net margin of -1688.87% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -75.88% beat EvoNext Holdings SA's return on equity of --.

AC Immune SA has a consensus price target of $9.20, signalling upside risk potential of 223.77%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that AC Immune SA has higher upside potential than EvoNext Holdings SA, analysts believe AC Immune SA is more attractive than EvoNext Holdings SA.

AC Immune SA has a beta of 1.637, which suggesting that the stock is 63.73% more volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -40.297, suggesting its less volatile than the S&P 500 by 4129.699%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $1.2M, which are larger than EvoNext Holdings SA quarterly revenues of --. AC Immune SA's net income of -$19.8M is higher than EvoNext Holdings SA's net income of --. Notably, AC Immune SA's price-to-earnings ratio is -- while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 55.40x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -1688.87% compared to AC Immune SA's net margin of 18.03%. AC Immune SA's return on equity of -75.88% beat Novartis AG's return on equity of 32.47%.

AC Immune SA has a consensus price target of $9.20, signalling upside risk potential of 223.77%. On the other hand Novartis AG has an analysts' consensus of $140.30 which suggests that it could fall by -11.73%. Given that AC Immune SA has higher upside potential than Novartis AG, analysts believe AC Immune SA is more attractive than Novartis AG.

AC Immune SA has a beta of 1.637, which suggesting that the stock is 63.73% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.47%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 2.42% to investors and pays a quarterly dividend of $3.99 per share. AC Immune SA pays -- of its earnings as a dividend. Novartis AG pays out 42.8% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

AC Immune SA quarterly revenues are $1.2M, which are smaller than Novartis AG quarterly revenues of $13.3B. AC Immune SA's net income of -$19.8M is lower than Novartis AG's net income of $2.4B. Notably, AC Immune SA's price-to-earnings ratio is -- while Novartis AG's PE ratio is 22.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 55.40x versus 5.89x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Santhera Pharmaceuticals Holding AG has a net margin of -1688.87% compared to AC Immune SA's net margin of --. AC Immune SA's return on equity of -75.88% beat Santhera Pharmaceuticals Holding AG's return on equity of 276.68%.

AC Immune SA has a consensus price target of $9.20, signalling upside risk potential of 223.77%. On the other hand Santhera Pharmaceuticals Holding AG has an analysts' consensus of -- which suggests that it could fall by --. Given that AC Immune SA has higher upside potential than Santhera Pharmaceuticals Holding AG, analysts believe AC Immune SA is more attractive than Santhera Pharmaceuticals Holding AG.

AC Immune SA has a beta of 1.637, which suggesting that the stock is 63.73% more volatile than S&P 500. In comparison Santhera Pharmaceuticals Holding AG has a beta of -0.872, suggesting its less volatile than the S&P 500 by 187.184%.

AC Immune SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Santhera Pharmaceuticals Holding AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AC Immune SA pays -- of its earnings as a dividend. Santhera Pharmaceuticals Holding AG pays out -- of its earnings as a dividend.

AC Immune SA quarterly revenues are $1.2M, which are larger than Santhera Pharmaceuticals Holding AG quarterly revenues of --. AC Immune SA's net income of -$19.8M is higher than Santhera Pharmaceuticals Holding AG's net income of --. Notably, AC Immune SA's price-to-earnings ratio is -- while Santhera Pharmaceuticals Holding AG's PE ratio is 1.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AC Immune SA is 55.40x versus 4.78x for Santhera Pharmaceuticals Holding AG. Usually stocks with elevated PS ratios are considered overvalued.